James D. Cox
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
James D. Cox has a total of 212 co-authors. Here are the top co-authors by number of shared publications:
- Ritsuko Komaki
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
13 shared publications Z. Liao
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
12 shared publicationsS.H. Lin
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
9 shared publicationsX. Wei
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
9 shared publicationsP.K. Allen
The University of Texas MD Anderson Cancer Center, Houston, TX
7 shared publicationsJ.Y. Chang
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
6 shared publications
Latest Publications
- Open Access
- 29 December 2018
- Published by Springer Nature in Radiation Oncology
- Vol. 13  (1) , 1-10
Outcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis
Small cell lung cancer (SCLC) can recur in the brain after whole-brain irradiation (WBI). We documented outcomes after treatment of such recurrences and sought predictors of local control and overall survival (OS). Eighty-five patients with SCLC and brain recurrence after prophylactic or therapeutic WBI in 1998–2015 were identified and data were extracted from the medical records. Survival was estimated with the Kaplan-Meier method, and univariate and multivariate Cox proportional hazards modeling was used to identify factors associated with OS or further brain progression. Brain recurrence was treated by stereotactic radiosurgery (SRS) in 33 patients (39%), repeat WBI in 14 (16%), chemotherapy-only in 16 (19%), and observation in 22 (26%). Median OS time after brain recurrence (OSrec) was 4.3 months for all patients; 6-month OSrec rates were 58% after SRS, 21% after repeat WBI, 50% after chemotherapy-only, and 5% after observation (P < 0.001). Inferior OSrec was associated with poor performance status (ECOG score ≥ 3) and uncontrolled extracranial disease. Superior OSrec was associated with receipt of ≥4 chemotherapy cycles before brain recurrence and receipt of chemotherapy, SRS, or repeat WBI afterward. Receipt of chemotherapy after brain recurrence correlated with brain progression. Some patients with brain recurrence after WBI for SCLC can survive for extended periods with appropriate intervention, especially those with adequate performance status or controlled extracranial disease.
- 29 December 2018
- Published by Springer Nature in Radiation Oncology
- Vol. 13  (1) , 1-10
Open AccessOutcomes of re-irradiation for brain recurrence after prophylactic or therapeutic whole-brain irradiation for small cell lung Cancer: a retrospective analysis
Small cell lung cancer (SCLC) can recur in the brain after whole-brain irradiation (WBI). We documented outcomes after treatment of such recurrences and sought predictors of local control and overall survival (OS). Eighty-five patients with SCLC and brain recurrence after prophylactic or therapeutic WBI in 1998–2015 were identified and data were extracted from the medical records. Survival was estimated with the Kaplan-Meier method, and univariate and multivariate Cox proportional hazards modeling was used to identify factors associated with OS or further brain progression. Brain recurrence was treated by stereotactic radiosurgery (SRS) in 33 patients (39%), repeat WBI in 14 (16%), chemotherapy-only in 16 (19%), and observation in 22 (26%). Median OS time after brain recurrence (OSrec) was 4.3 months for all patients; 6-month OSrec rates were 58% after SRS, 21% after repeat WBI, 50% after chemotherapy-only, and 5% after observation (P < 0.001). Inferior OSrec was associated with poor performance status (ECOG score ≥ 3) and uncontrolled extracranial disease. Superior OSrec was associated with receipt of ≥4 chemotherapy cycles before brain recurrence and receipt of chemotherapy, SRS, or repeat WBI afterward. Receipt of chemotherapy after brain recurrence correlated with brain progression. Some patients with brain recurrence after WBI for SCLC can survive for extended periods with appropriate intervention, especially those with adequate performance status or controlled extracranial disease.
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99  (2) , E484-E485
Reported Outcomes and Toxicities for Inoperable, Stage II-III Non–Small Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and Intensity Modulated Proton Therapy
- 1 October 2017
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 99  (2) , E484-E485
Reported Outcomes and Toxicities for Inoperable, Stage II-III Non–Small Cell Lung Cancer Patients Treated with Concurrent Chemotherapy and Intensity Modulated Proton Therapy
- 1 October 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96  (2) , E430
Incidence of and Survival Outcomes After Metachronous Second Primary Malignancy After the Treatment of Limited-Stage Small Cell Lung Cancer
- 1 October 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96  (2) , E430
Incidence of and Survival Outcomes After Metachronous Second Primary Malignancy After the Treatment of Limited-Stage Small Cell Lung Cancer
- 1 October 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96  (2) , E454-E455
Immediately Concurrent Chemoradiation Therapy Is Associated With Improved 2-Year Overall Survival in Patients With Limited Small-Cell Lung Cancer
- 1 October 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 96  (2) , E454-E455
Immediately Concurrent Chemoradiation Therapy Is Associated With Improved 2-Year Overall Survival in Patients With Limited Small-Cell Lung Cancer
- 1 May 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 95  (1) , 4-8
Impediments to Comparative Clinical Trials With Proton Therapy
- 1 May 2016
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 95  (1) , 4-8
Impediments to Comparative Clinical Trials With Proton Therapy
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93  (3) , E402-E403
PET Metabolic Tumor Response by PERCIST Reliably Predicts Local Regional Control in Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy With Erlotinib
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93  (3) , E402-E403
PET Metabolic Tumor Response by PERCIST Reliably Predicts Local Regional Control in Locally Advanced Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy With Erlotinib
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93  (3) , E436-E437
Factors Associated With Severe Pneumonitis for Limited Stage Small Cell Lung Cancer
- 1 November 2015
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 93  (3) , E436-E437
Factors Associated With Severe Pneumonitis for Limited Stage Small Cell Lung Cancer
- 1 November 2014
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 90  (5) , S66-S67
Nadir White Blood Cell, Absolute Neutrophil, and Absolute Lymphocyte Counts During Concurrent Chemoradiation Therapy Are Associated With Worse Outcomes in Patients With Limited-Stage Small Cell Lung Cancer
- 1 November 2014
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 90  (5) , S66-S67
Nadir White Blood Cell, Absolute Neutrophil, and Absolute Lymphocyte Counts During Concurrent Chemoradiation Therapy Are Associated With Worse Outcomes in Patients With Limited-Stage Small Cell Lung Cancer
- Open Access
- 6 May 2014
- Published by Springer Nature in Radiation Oncology
- Vol. 9  (1) , 108
Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial
We assessed the robustness of passive scattering proton therapy (PSPT) plans for patients in a phase II trial of PSPT for stage III non-small cell lung cancer (NSCLC) by using the worst-case scenario method, and compared the worst-case dose distributions with the appearance of locally recurrent lesions.
- 6 May 2014
- Published by Springer Nature in Radiation Oncology
- Vol. 9  (1) , 108
Open AccessAssessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial
We assessed the robustness of passive scattering proton therapy (PSPT) plans for patients in a phase II trial of PSPT for stage III non-small cell lung cancer (NSCLC) by using the worst-case scenario method, and compared the worst-case dose distributions with the appearance of locally recurrent lesions.